molmed.com
MolMed S.p.A.MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of innovative therapies to treat cancer.
http://www.molmed.com/
MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of innovative therapies to treat cancer.
http://www.molmed.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Monday
LOAD TIME
0.5 seconds
MOLMED SPA
Via O●●●●●na 58
Mi●●no , 20132
IT
View this contact
Fastweb Spa
Fastweb Spa
Via Ca●●●●●●olo 51
Mi●●no , 20155
IT
View this contact
Register.it S.p.A.
Register.it S.p.A.
Via Mo●●●●●●ri s/n
Be●●mo , 24126
IT
View this contact
BUY YOUR DOMAIN
24
YEARS
3
MONTHS
22
DAYS
REGISTER.IT SPA
WHOIS : whois.register.it
REFERRED : http://we.register.it
PAGES IN
THIS WEBSITE
19
SSL
EXTERNAL LINKS
27
SITE IP
176.58.106.33
LOAD TIME
0.547 sec
SCORE
6.2
MolMed S.p.A. | molmed.com Reviews
https://molmed.com
MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of innovative therapies to treat cancer.
molmed.com
MolMed S.p.A.
http://www.molmed.com/node/2698
Our goal is to provide physicians and patients with innovative and effective therapies for the treatment of cancers for which current treatment options are limited. To achieve this, we are carrying out clinical trials on two distinct investigational therapies, both new and complementary to each other, completely original founders of new therapeutic classes:. Main results of clinical trials. Cell and Gene therapy. SpA Via Olgettina, 58 - 20132 Milano, Italy. Phone 39 0221277.1 - Fax 39 02 21277.325.
MolMed S.p.A.
http://www.molmed.com/node/41
Nov 10, 2015. Notice of ordinary shareholders' meeting. Aug 1, 2014. Notice of ordinary and extraordinary Shareholders' Meeting. May 14, 2014. Financial report at 31 march 2014 (in Italian). Annual financial report (English translation for convenience) 2015. Half-year financial report -English translation for convenience at. Interim financial report (English translation for convenience) at. Interim financial report (in Italian) at. Guidelines for the internal control system (in Italian). Jun 10, 2016.
MolMed S.p.A.
http://www.molmed.com/node/2014
Online Investor kit delivers some useful tools. To request additional documents or information, please complete the Investor contact form. Relazione finanziaria annuale 2013 [3.88 MB]. Presentazione delle società Jefferies Conference NYC giugno 2014 (in inglese) [1.25 MB]. Annual financial report (English translation for convenience) 2013 [1.6 MB]. Company presentation Jefferies Conference NYC June 2014 [1.25 MB]. Investor Relations and Communication Director. Phone: 39 02 21277.1. Name and Surname *.
MolMed S.p.A.
http://www.molmed.com/node/23
Through scientific innovation, MolMed. Continuously develops in-house expertise in cell/genetic engineering and in peptide-targeted technology. Cell and Gene therapy. Aug 22, 2016. The European Commission grants a Conditional Marketing Authorisation to Zalmoxis. Aug 1, 2016. The Board of Directors approves the first half-year financial report ended June 30, 2016. Jul 1, 2016. MolMed receives positive COMP opinion on the orphan drug designation for Zalmoxis(R). Subscribe to press releases.
MolMed S.p.A.
http://www.molmed.com/node/19
The European Commission grants marketing authorisation to gene therapy for ADA-SCID. May 30, 2016. Positive opinion issued by the Committee for Medicinal Products for Human Use on GSK stem cell therapy for ADA-SCID patients. Apr 2, 2016. MolMed winner of sixth edition of the Annual Most Innovative EU Biotech SME Award. Jun 23, 2015. Oct 18, 2016. Oct 21, 2016. Sep 11, 2016. Sep 13, 2016. Rodman and Renshaw 18th annual Global Investment Conference. Sep 9, 2016. Sep 11, 2016. Sep 9, 2016. Jun 10, 2016.
TOTAL PAGES IN THIS WEBSITE
19
Partners | supersist
http://www.supersist-project.eu/partners
Università Vita-Salute San Raffaele. The German Cancer Research Center. Christof von Kalle, MD, PhD. The Netherlands Cancer Institute. Prof dr. Ton NM Schumacher. Last News and Events. Mar, 18th, 2014. XXIInd Annual ESGCT Congress with NVGCT. Oct, 23th, 2014. To Oct, 26th, 2014. Oct, 07th, 2013. This project has received funding from the European Union’s Seventh Programme for research, technological development and demonstration under grant agreement No. 601958. SUPERSIST Project 2013 - 2016.
Abstract awards & prizes at EBMT 2016
http://www.ebmt2016.org/awards-and-prizes.html
Of the European Society for. Blood and Marrow Transplantation. 3 6 April 2016 Valencia, Spain. Of the European Society for. Blood and Marrow Transplantation. 3 6 April 2016 Valencia, Spain. Sign up for updates. Patient, Family and Donor Day. Working Party Business Meetings. EBMT 2016 fact sheet. EBMT 2016 photo gallery. EBMT 2015 fact sheet. The EBMT is pleased to offer a growing number of awards and prizes for abstracts submitted for Oral and Poster presentation at the EBMT annual congress. To qualify f...
Travel to Valencia, Spain
http://www.ebmt2016.org/travel.html
Of the European Society for. Blood and Marrow Transplantation. 3 6 April 2016 Valencia, Spain. Of the European Society for. Blood and Marrow Transplantation. 3 6 April 2016 Valencia, Spain. Sign up for updates. Patient, Family and Donor Day. Working Party Business Meetings. EBMT 2016 fact sheet. EBMT 2016 photo gallery. EBMT 2015 fact sheet. Valencia can be reached by car, train, car and boat. Taxis, busses and the metro all take you into the city within 15 minutes. EVA Airways, EgyptAir, Ethiopian Airli...
City - Valencia
http://www.ebmt2016.org/city-valencia.html
Of the European Society for. Blood and Marrow Transplantation. 3 6 April 2016 Valencia, Spain. Of the European Society for. Blood and Marrow Transplantation. 3 6 April 2016 Valencia, Spain. Sign up for updates. Patient, Family and Donor Day. Working Party Business Meetings. EBMT 2016 fact sheet. EBMT 2016 photo gallery. EBMT 2015 fact sheet. View the Online Programme. First day of conference. EBMT 2016 EHA-CME accreditation. C/o MCI Suisse SA. 41 22 33 99 581. 41 22 33 99 631. Avinguda de les Fires, 1.
Abstracts
http://www.ebmt2016.org/abstracts.html
Of the European Society for. Blood and Marrow Transplantation. 3 6 April 2016 Valencia, Spain. Of the European Society for. Blood and Marrow Transplantation. 3 6 April 2016 Valencia, Spain. Sign up for updates. Patient, Family and Donor Day. Working Party Business Meetings. EBMT 2016 fact sheet. EBMT 2016 photo gallery. EBMT 2015 fact sheet. How to prepare your oral presentation, please click HERE. How to prepare your poster presentation, please click HERE. Please download the presentation template HERE.
Comitato di Presidenza
http://assobiotec.federchimica.it/chi-siamo/comitato-di-presidenza
Parchi scientifici e tecnologici. Mettersi in proprio nel Biotech. Biotecnologie per la salute. Biotecnologie per le PMI. Cosa sono le Biotecnologie. Che cos'è la Bioeconomia. Parchi scientifici e tecnologici. Mettersi in proprio nel Biotech. Biotecnologie per la salute. Biotecnologie per le PMI. Cosa sono le Biotecnologie. Che cos'è la Bioeconomia. Biotecnologie per la salute. Piccole e Medie Imprese/SME. Farmaci biotecnologici e biosimilari. Dalla ricerca biotecnologica nuove risorse per la nutrizione.
Pansoft - Referenze
http://www.pansoft.it/ref.htm
You need to upgrade your Flash Player. 2015 Pansoft S.r.l. Tra i settori merceologici in cui Pansoft ha conseguito i suoi maggiori successi, spiccano: il medicale, il biotech, l'industria meccanica, i servizi logistici e la distribuzione. Possiamo affermare senza timore di essere smentiti di essere una tra le pochissime società di consulenza e progetti IT che nel corso di tutta la sua storia non abbia mai fallito un progetto. Strumenti e Reagenti diagnostici. Benind - Gruppo BENETTON. Ex PPM e Bendini).
EBMT 2016 -- Congress Information: Press
http://www.ebmt2016.org/press.html
Of the European Society for. Blood and Marrow Transplantation. 3 6 April 2016 Valencia, Spain. Of the European Society for. Blood and Marrow Transplantation. 3 6 April 2016 Valencia, Spain. Sign up for updates. Patient, Family and Donor Day. Working Party Business Meetings. EBMT 2016 fact sheet. EBMT 2016 photo gallery. EBMT 2015 fact sheet. Here you can find the EBMT Industry Media Policy. Press Conference Room / Press Interview Room Reservation Forms will be available soon. View the Online Programme.
TOTAL LINKS TO THIS WEBSITE
27
www.molmed-goettingen.de
AMGP: Ajou University Molecular Medicine Graduate Program
Research Highlights @ ANGP. Silver nanoparticles affect glucose metabolism in hepatoma cells through production of reactive oxygen species (International Jour. 박선 교수 연구팀, 은나노입자가 활성산소 생산을 통해 당대사에 변화를 초래함을 밝힘). Silver nanoparticles (AgNPs) affect glucose metabolism. International Conference of the Korean Society for Molecular and Cellular Biology. 구기방 통합과정 학생이 국제학술대회 [아모레퍼시픽 차세대 연구자] 상을 수상하여 이백만원의 상금을 받았으며 연구내용을 발표 함. 이광 교수 연구팀, 실리카 코팅 자성 나노입자 의 통합오믹스적 나노독성 분석). Immunobiology. 2015, 220(12):1381-92). Cell-...
پزشکی در سطح مولکول
پزشکی در سطح مولکول. بیماری پارکینسون در اثر تحلیل سلولهای مغزی در سنین بالای 60 سال رخ میدهد و تقریبا 66% بیماران طی 5 سال اول بیماری و 80% پس از 10 سال دچار ناتوانی میگردند. پارکینسن یک بیماری دژنراتیو عصبی، ناتوانکننده و پیشرونده است که توسط جیمزپارکینسون در سال 1817 توصیف شد. مشخصات بیماری عبارتند از حرکت کند و کاهش یافته، سفتی و لرزش عضلانی و عدم تعادل، جویدن ناقص، اختلال در بلع و در سخن گفتن. سه فرضیه در مورد علت شناسی پارکینسون وجود دارد:. تغییر متابولیسم دوپامین در اثر یک جراحت عصبی. در حال حاضر ...
MolMed S.p.A.
Alliance for Regenerative Medicine. Luca Alberici, Ph.D.,. Professor Mohamad Mohty (EBMT President) at the 58th Annual Meeting of the American Society of Hematology (ASH). SpA is a medical biotechnology company focused on research, development and clinical validation of innovative therapies to treat cancer. Apr 17, 2018. 6th Annual Cell and Gene Therapy Investor Day 17 april NY. Apr 3, 2018. Tg2 Medicina33 Haploidentical transplantation and new cell therapies, interview with Fabio Ciceri. Feb 1, 2018.
molmed.humanmedizin-goettingen.de
Diese Domain wurde bei EDIS registriert! DE
Webhosting und vserver in Österreich, Deutschland, Schweiz, England, Italien, USA, Frankreich, Island, Poland, Spanien, Chile, Hongkong, Isle of Man, . Ist Ihre Wunschdomain noch verfügbar? PHP7 Webhosting Oesterreich mit der besten e-Mail-Sicherheitsloesung der Welt. Let's Encrypt SSL Zertifikate. Enterprise Dedicated Server HP Proliant DL360 Vienna Austria.
MolMed S.p.A.
Alliance for Regenerative Medicine. Luca Alberici, Ph.D.,. Professor Mohamad Mohty (EBMT President) at the 58th Annual Meeting of the American Society of Hematology (ASH). SpA is a medical biotechnology company focused on research, development and clinical validation of innovative therapies to treat cancer. Apr 17, 2018. 6th Annual Cell and Gene Therapy Investor Day 17 april NY. Apr 3, 2018. Tg2 Medicina33 Haploidentical transplantation and new cell therapies, interview with Fabio Ciceri. Feb 1, 2018.
東京都医学総合研究所 分子医療PT of MolMed Research
7月 8日 感染症サイトカイン研究会 神戸 世話人会 松田浩珍先生発表. 6月30日 7月1日 第17回CBSM 大会長 医学研 芝崎 太 が伊豆熱海で開催されます。 5月23日 NGS学会 大保木 仙台. 5月15日 東京理科大理工学部講義 2 芝崎. 5月14日 医学研 連係大学院説明会 医学研. 5月12日 TOBIRA主催 第6回研究フォーラム お茶の水 ソラシティー. 5月 8日 東京理科大理工学部講義 1 芝崎. 4月 1日 新しく後藤紗季、入江 敦の二名の常勤研究員が当研究プロジェクトに加わりました。 組合 とびら)、主催権研究会としてConference for BioSignal and Medicine CBSM)を毎年開催しております。
Molekulare Medizin - Universität Erlangen - Molekulare Medizin - Universität Erlangen
Allgemeine Informationen zum Studienprogramm. To-Do-Liste für Erstsemester (Bachelor). To-Do-Liste für Erstsemester (Master). The old order changeth, yielding place to the new.". Alfred Lord Tennyson (1886). Auf der Webseite des B.Sc./M.Sc. Studienprogramms. Please update your Flash Player. Montag, 12.10.2015 um 08:00. Studienbeginn Bachelor Molekulare Medizin. Wir freuen uns darauf, Sie im Oktober kennen zu lernen! Montag, 12.10.2015 um 08:00. Studienbeginn Master Molekulare Medizin.
Welcome to Molecular Medicine, Department of Medical Sciences - Uppsala University, Sweden
Department of Medical Sciences. Prof Ann-Christine Syvänen. Ann-Christine.Syvanen@medsci.uu.se. Department of Medical Sciences. For additional contact information. Welcome to Molecular Medicine, Department of Medical Sciences. In Molecular Medicine headed by Professor Ann-Christine Syvänen was started in 1998. The group studies human diseases using modern technology for genomics. Professor Syvänen also heads the SNP&SEQ Technology Platform. Use the tab-menu above to view information about our research.
